Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To study the efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar I or II depression with comorbid generalized anxiety disorder (GAD) and other comorbidities. METHOD: The study was conducted from January 2007 to November 2011. The Mini-International Neuropsychiatric Interview was used to ascertain the diagnosis of DSM-IV bipolar disorder, GAD, and other Axis I disorders. Eligible patients were randomly assigned to quetiapine-XR or placebo for up to 8 weeks. The Hamilton Depression Rating Scale-17 items (HDRS-17) was used as a primary outcome to evaluate the difference between the 2 groups using the change from baseline to end of study. Last observation carried forward and mixed-effects modeling for repeated measures were used to analyze the primary and secondary outcome measures. RESULTS: Of the 120 patients screened, 100 patients were randomized to receive quetiapine-XR (n = 50) or placebo (n = 50). Twenty-six patients in the quetiapine-XR and 18 in the placebo group completed the study. The mean quetiapine-XR dose was 276 ± 50 mg/d (50-300 mg/d). There was no significant difference between the 2 groups in the change from baseline to end of study in HDRS-17 total score with an effect size of 0.19 favoring quetiapine-XR. There were also no significant differences between the 2 groups in secondary efficacy and safety outcome measures. CONCLUSIONS: Quetiapine-XR was not significantly superior to placebo in bipolar I or II depression with GAD and other comorbidities, suggesting that data from relatively "pure" bipolar patients may not be generalizable to a highly comorbid population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00671853.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Quetiapine failed to provide any benefit in terms of mood and anxiety symptoms in a small subsample of highly comorbid patients with BD. generalized anxiety disorder (GAD) and cannabis use disorder701 (level 3 negative).”
In the citing paper
“No significant improvement was found in depressive or anxiety symptoms but alcohol or substance use‐related outcomes were not reported separately.”
Citations
Cites
Still being checked.
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationFountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Prisciandaro, J. J., Tolliver, B. K., Prescot, A. P., Brenner, H. M., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.141 · Cited by 80
Metadata
- Authors
- Gao, K., Wu, R., Kemp, D. E., Chen, J., Karberg, E., Conroy, C., Chan, P., Ren, M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R.
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Central South University (CN)
- Shanghai Jiao Tong University (CN)
- Case Western Reserve University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-06-24
- Volume
- 75
- Issue
- 10
- Pages
- 1062-1068
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1980958940
- Cited by
- 29
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2021: 3 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 7
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar depression, generalized anxiety disorder, comorbidities, adjunctive therapy, mood stabilizers, monotherapy, atypical antipsychotics, treatment efficacy, drug safety
- MeSH terms
- Quetiapine Fumarate, Acute Disease, Adult, Anxiety Disorders, Bipolar Disorder, Delayed-Action Preparations, Dibenzothiazepines, Double-Blind Method, Drug Synergism, Female, Humans, Male, Middle Aged, Placebos, Antipsychotic Agents, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.13m08847
- The paper
- Gao, K., Wu, R., Kemp, D. E., Chen, J., Karberg, E., Conroy, C., Chan, P., Ren, M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R. (2014). Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.